Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
epigenetic aging and autosomal methylation remodeling in anderson fabry disease
Original title: “Epigenetic aging and autosomal methylation remodeling in Anderson-Fabry disease.”
Japan's early-access framework, South Korea's insurance coverage for enzyme replacement therapy, and China's expanded rare disease reimbursement policies are accelerating treatment availability. Growing clinical trial activity and healthcare infrastructure investment in India and Southeast ... Japan's early-access framework, South Korea's insurance coverage for enzyme replacement therapy, and China's expanded rare disease reimbursement policies are accelerating treatment availability. Growing clinical trial activity and healthcare infrastructure investment in India and Southeast Asia are expected to create additional opportunities through 2031. Expanded screening is identifying more Fabry patients, while gene, mRNA and oral therapies offer less burdensome, personalized care, with strong... Conversely, orphan-drug incentives, fast-track regulatory designations, and increased healthcare spending on rare diseases are expected to support future market expansion. Enzyme Replacement Therapy Maintains Market Leadership · Enzyme replacement therapy accounted for 67.85% of Fabry disease treatment market revenue in 2025. Its established safety profile and extensive clinical use continue to support its position as a primary treatment approach. North America generated 42.85% of global market revenue in 2025, supported by newborn screening, specialist treatment centers, established reimbursement systems, and active clinical trial recruitment. Regulatory pathways offering priority review and breakthrough designations are also encouraging faster adoption of innovative Fabry disease therapies across the United States and Canada.
Original title: “Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy”
prevalence of fabry disease gla variants among patients with parapelvic cysts a multicenter italian cohort study
Original title: “Prevalence of Fabry disease GLA variants among patients with parapelvic cysts: a Multicenter Italian Cohort Study.”
long term cardiac remodeling during migalastat therapy in a heterozygote woman with fabry disease n224s a 9 year case report
Original title: “Long-Term Cardiac Remodeling During Migalastat Therapy in a Heterozygote Woman With Fabry Disease (N224S): A 9 Year Case Report.”
paradoxical apparent native t1 elevation in triglyceride deposit cardiomyovasculopathy a pitfall in contrast with fabry disease
Original title: “Paradoxical Apparent Native T1 Elevation in Triglyceride Deposit Cardiomyovasculopathy: A Pitfall in Contrast With Fabry Disease.”
myocardial inflammation and scar expansion in patients with anderson fabry disease
Original title: “Myocardial inflammation and scar expansion in patients with Anderson-Fabry disease.”
fabry disease cardiac and neurologic involvement
Original title: “Fabry Disease: Cardiac and Neurologic Involvement.”
fabry disease cardiomyopathy time for a closer heart rhythm monitoring
Original title: “Fabry disease cardiomyopathy: Time for a closer heart rhythm monitoring?”
evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with fabry disease receiving enzyme replacement therapy a systematic literature review
Original title: “Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review.”
real world outcomes of fabry disease in italian excellence centers the ground study
Original title: “Real world outcomes of Fabry disease in Italian excellence centers: the ground study.”
sudden cardiac death and major arrhythmic events in patients with fabry disease risk stratification in the fhfc multicenter study
Original title: “Sudden cardiac death and major arrhythmic events in patients with Fabry disease: risk stratification in the FHFc multicenter study.”
impact of migalastat therapy on corneal deposits in a female with fabry disease a case report
Original title: “Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report.”
correction correlation of retinal vascular characteristics with laboratory and ocular findings in fabry disease exploring ocular diagnostic biomarkers
Original title: “Correction: Correlation of retinal vascular characteristics with laboratory and ocular findings in Fabry disease: exploring ocular diagnostic biomarkers.”
neurological management and outcome measures in fabry disease consensus statements from the italian fabry disease neurological working group
Original title: “Neurological management and outcome measures in Fabry disease: consensus statements from the Italian Fabry disease neurological working group.”
development and validation of a self management efficacy questionnaire for patients with fabry disease in china
Original title: “Development and validation of a self-management efficacy questionnaire for patients with Fabry disease in China.”
concurrent fabry disease and monoclonal gammopathy of renal significance a case report
Original title: “Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report.”
treatment related benefit and satisfaction in patients with fabry disease in france insight into patients expectations and preferences from the prospective non interventional satis fab study
Original title: “Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients' expectations and preferences from the prospective, non-interventional SATIS-Fab study.”